title: Response to Letter Regarding Article, “Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction”.
authors.forename: Robin A P
authors.initials: RA
authors.lastname: Weir
authors.forename: Colin J
authors.initials: CJ
authors.lastname: Petrie
authors.forename: C Aengus
authors.initials: CA
authors.lastname: Murphy
authors.forename: Suzanne
authors.initials: S
authors.lastname: Clements
authors.forename: Tracey
authors.initials: T
authors.lastname: Steedman
authors.forename: Ashley M
authors.initials: AM
authors.lastname: Miller
authors.forename: Iain B
authors.initials: IB
authors.lastname: McInnes
authors.forename: Iain B
authors.initials: IB
authors.lastname: Squire
authors.forename: Leong L
authors.initials: LL
authors.lastname: Ng
authors.forename: Henry J
authors.initials: HJ
authors.lastname: Dargie
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
mesh_terms: D005260:Female; D037502:Galectin 3 / Q000097:blood*; D006801:Humans; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology*; D009203:Myocardial Infarction / Q000097:blood* / Q000401:mortality*; D013148:Spironolactone / Q000031:analogs & derivatives*; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology*; D020257:Ventricular Remodeling / Q000502:physiology*
chemical_list: D037502:Galectin 3; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone